Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,421
  • Shares Outstanding, K 27,417
  • Annual Sales, $ 103,460 K
  • Annual Income, $ -227,210 K
  • EBIT $ -101 M
  • EBITDA $ -88 M
  • 60-Month Beta 1.51
  • Price/Sales 1.46
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 125.27% ( -1.55%)
  • Historical Volatility 143.13%
  • IV Percentile 20%
  • IV Rank 12.41%
  • IV High 452.62% on 11/12/24
  • IV Low 78.88% on 10/11/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,733
  • Volume Avg (30-Day) 620
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 14,493
  • Open Int (30-Day) 18,052

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.78
  • Number of Estimates 1
  • High Estimate -0.78
  • Low Estimate -0.78
  • Prior Year -2.52
  • Growth Rate Est. (year over year) +69.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.34 +19.35%
on 07/01/25
6.20 -16.45%
on 07/03/25
-0.77 (-12.94%)
since 06/06/25
3-Month
1.56 +232.05%
on 04/10/25
6.35 -18.43%
on 06/06/25
+3.34 (+181.52%)
since 04/07/25
52-Week
1.38 +275.36%
on 04/07/25
18.74 -72.36%
on 07/16/24
-9.95 (-65.76%)
since 07/05/24

Most Recent Stories

More News
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

Apellis Pharmaceuticals’ APLS shares gained 3.2% on Tuesday following the announcement of a capped royalty deal with Sobi, under which Apellis will receive up to $300 million in return for 90% of its...

AGEN : 5.18 (-14.66%)
IMCR : 32.41 (-1.85%)
VRNA : 91.20 (-0.36%)
APLS : 17.42 (-4.60%)
Investors Bet on Biotech as Public Cancer Research Hits a Wall

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more affordable treatments...

ONCY : 1.0100 (+9.79%)
AGEN : 5.18 (-14.66%)
OLMA : 4.45 (-2.63%)
ICCM : 1.0500 (-0.47%)
ONC.TO : 1.37 (+19.13%)
ATNM : 1.4200 (-1.39%)
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies

/CNW/ -- Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus' today announced its entry into the global biologics...

AGEN : 5.18 (-14.66%)
Allogene's Q1 Earnings In Line With Estimates, Sales Nil

Allogene Therapeutics ALLO incurred first-quarter 2025 loss of 28 cents per share, which matched the Zacks Consensus Estimate. In the year-ago period, the company had incurred a loss of 38 cents per share.As...

ALLO : 1.1600 (-2.52%)
AGEN : 5.18 (-14.66%)
ELEV : 0.3790 (-2.32%)
ADPT : 11.74 (-0.51%)
Agenus: Q1 Earnings Snapshot

Agenus: Q1 Earnings Snapshot

AGEN : 5.18 (-14.66%)
Agenus (AGEN) Q4 2024 Earnings Call Transcript

AGEN earnings call for the period ending December 31, 2024.

AGEN : 5.18 (-14.66%)
Agenus: Q4 Earnings Snapshot

Agenus: Q4 Earnings Snapshot

AGEN : 5.18 (-14.66%)
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

/CNW/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25 in...

ONCY : 1.0100 (+9.79%)
AGEN : 5.18 (-14.66%)
GH : 49.54 (-1.90%)
XLO : 0.6993 (+0.19%)
ONC.TO : 1.37 (+19.13%)
RNXT : 1.3200 (-2.94%)
Agenus (AGEN) Q3 2024 Earnings Call Transcript

AGEN earnings call for the period ending September 30, 2024.

AGEN : 5.18 (-14.66%)
Agenus: Q3 Earnings Snapshot

Agenus: Q3 Earnings Snapshot

AGEN : 5.18 (-14.66%)

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

3rd Resistance Point 6.95
2nd Resistance Point 6.47
1st Resistance Point 5.82
Last Price 5.18
1st Support Level 4.69
2nd Support Level 4.21
3rd Support Level 3.56

See More

52-Week High 18.74
Fibonacci 61.8% 12.11
Fibonacci 50% 10.06
Fibonacci 38.2% 8.01
Last Price 5.18
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar